Clinical significance of hemostatic markers and thrombomodulin in systemic lupus erythematosus: Evidence for a prothrombotic state

Lupus

Volumn 8, Issue 9, 1999, Pages 737-741

  Kiraz, S ^a,b   Ertenli, I ^a   Benekli, M ^a   Haznedaroglu I C ^a   Calguneri M ^a   Celik I ^a   Apraş, Ş ^a   Kirazli, Ş ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b 35 Sokak No: 112/13 ^*  (Turkey)

Author keywords

Coagulation; Fibrinolysis; Hemostasis thrombosis; Systemic lupus erythematosus; Thrombomodulin

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTITHROMBIN; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DNA ANTIBODY; PHOSPHOLIPID ANTIBODY; PLASMIN; PREDNISOLONE; PROTHROMBIN; THROMBIN; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ARTICLE; BLOOD CLOTTING; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; VASCULAR ENDOTHELIUM;

EID: 0032744986     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120399678840918     Document Type: Article

References (27)

1. Pétri M. Thrombosis and systemic lupus erythematosus: The Hopkins lupus cohort perspective. Scand J Rheumatol 1996; 25: 191-193.
2. Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Arthritis Rheum 1996; 39: 9-22.
3. Hasselaar P, Derksen RHWM, Blokzijl L et al. Risk factors for thrombosis in lupus patients. Ann Rheum Dis 1989; 48: 933-940.
4. Kabakov AE, Tertov VV, Saenko VA et al. The atherogenic effect of lupus sera. Clin Immunol Immunopathol 1992; 63: 214-220.
5. Fauci AS, Hayne BF, Katz P. The spectrum of vasculitis. Ann Intern Med 1978; 89: 660-1376.
6. Inoh M, Tokuda M, Kiuchi H et al. Evaluating systemic lupus erythematosus disease activity using molecular markers of hemostasis. Arthritis Rheum 1996; 39: 287-291.
7. Boey ML, Colaco CB, Gharavi AE et al. Thrombosis in systemic lupus erythematosus: Striking association with the presence of circulating lupus anticoagulant. BMJ 1983; 287: 1021-1023.
8. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
9. Bombardier C, Gladman DD, Urowitz MB et al. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640.
10. Fareed J, Bick RL, Hoppensteadt DA, Bennes EW. Molecular markers of hemostatic activation: Applications in the diagnosis of thrombosis and vascular and thrombotic disorders. Clin Appl Thromb Hemost 1995; 1: 87-102.
11. Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59: 101-106.
12. Hursting MJ, Stead AG, Crout FV et al. Effects of age, race, sex, and smoking on prothrombin fragment 1.2 in a healthy population. Clin Chem 1993; 39: 683-686.
13. Wiman B, Collen D. On the mechanism of the reaction between human α2-antiplasmin and plasmin. J Biol Chem 1979: 254: 9291-9297.
14. Novotny WF. Tissue factor pathway inhibitor. Semin Thromb Haemost 1994; 20: 101-108.
15. Takano S. Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health diseases. Blood 1990; 76: 2024-2020.
16. Esmon NL. Thrombomodulin. Semin Thromb Haemost 1987; 13: 454-463.
17. Ishii H, Majerus PW. Thrombomodulin is present in human plasma and urine. J Clin Invest 1985; 76: 2178.
18. Cucurull E, Gharavi AE. Thrombomodulin: A new frontier in lupus research? Clin Exp Rheumatol 1997; 15: 1-4.
19. Ohdama S, Yoshizawa Y, Kubota T, Aoki N. Plasma thrombomodulin as an indicator of thromboembolic disease in systemic lupus erythematosus. Int J Cardiol 1994; 47(suppl): S1-S6.
20. Ohdama S, Takano S, Miyake S et al. Plasma thrombomodulin as a marker of vascular injuries in collagen vascular diseases. J Clin Pathol 1994; 101: 109-113.
21. Bochme MWJ, Nawroth PP, Kling E et al. Serum thrombomodulin: A novel marker of disease activity in systemic lupus erythematosus. Arthritis Rheum 1994; 37: 572-577.
22. Wada H, Ohiwa M, Kaneko T et al. Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation. Am J Hematol 1992; 39: 20-24.
23. Oida K, Takai H, Maeda H et al. Plasma thrombomodulin concentrations in diabetes mellitus. Diabetes Res Clin Pract 1990; 10: 193-196.
24. Tomura S, Nakamura Y, Deguchi F et al. Plasma von Willebrand factor and thrombomodulin as markers of vascular disorders in patients undergoing regular hemodialysis therapy. Thromb Res 1990; 58: 413-419.
25. Ishii H, Uchiyama H, Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 1991; 65: 618-623.
26. Takahashi H, Tatewaki W, Wada K et al. DDAVP does not induce the release of thrombomodulin from endothelial cells. Thromb Haemost 1991; 65: 451.
27. Takahashi H, Ito S, Hanano M et al. Circulating thrombomodulin as a novel endothelial cell marker: comparison of its behaviour with von Willebrand factor and tissue-type plasminogen activator. Am J Hematol 1992; 41: 32-39.